9-ING-41

CAS No. 1034895-42-5

9-ING-41( —— )

Catalog No. M22563 CAS No. 1034895-42-5

9-ING-41 is a glycogen synthase kinase-3 inhibitor.9-ING-41 (2, 4 μM; 48 hours) decreases neuroblastoma cell viability induces apoptosis[2]. 9-ING-41 (0.1-1 μM) inhibits GSK-3 leading to a decreased expression of the NF-κB target XIAP and significant apoptosis in neuroblastoma cells as shown by PARP cleavage, an apoptosis marker[1]. 9-ING-41 (0.5, 1.0, 1.5, 2.0 μM) inhibits the proliferation rate of all TCL and MCL lines with concentrations as low as 1.0 mM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 58 In Stock
5MG 91 In Stock
10MG 149 In Stock
25MG 309 In Stock
50MG 447 In Stock
100MG 668 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    9-ING-41
  • Note
    Research use only, not for human use.
  • Brief Description
    9-ING-41 is a glycogen synthase kinase-3 inhibitor.9-ING-41 (2, 4 μM; 48 hours) decreases neuroblastoma cell viability induces apoptosis[2]. 9-ING-41 (0.1-1 μM) inhibits GSK-3 leading to a decreased expression of the NF-κB target XIAP and significant apoptosis in neuroblastoma cells as shown by PARP cleavage, an apoptosis marker[1]. 9-ING-41 (0.5, 1.0, 1.5, 2.0 μM) inhibits the proliferation rate of all TCL and MCL lines with concentrations as low as 1.0 mM.
  • Description
    9-ING-41 is a glycogen synthase kinase-3 inhibitor.9-ING-41 (2, 4 μM; 48 hours) decreases neuroblastoma cell viability induces apoptosis. 9-ING-41 (0.1-1 μM) inhibits GSK-3 leading to a decreased expression of the NF-κB target XIAP and significant apoptosis in neuroblastoma cells as shown by PARP cleavage, an apoptosis marker. 9-ING-41 (0.5, 1.0, 1.5, 2.0 μM) inhibits the proliferation rate of all TCL and MCL lines with concentrations as low as 1.0 mM. 9-ING-41 (1, 2 μM; 24 hours) is a potent cell cycle-blocking agent for lymphoma cells[2].9-ING-41 (40 mg/kg/every other day; for 17 days) has single-agent antitumor activity in a mouse model of MCL.
  • In Vitro
    Cell Viability Assay Cell Line:TCL and MCL lines Concentration:2, 4 μM Incubation Time:48 hours Result:Induced apoptosis.Cell Cycle Analysis Cell Line:Lymphoma cells (Jeko, Mino, and OCI-Ly cell lines) Concentration:1, 2 μM Incubation Time:24 hours Result:Led to cell cycle arrest in G2/M.Cell Autophagy Assay Cell Line:T24 cancer cells Concentration:25?μM Incubation Time:24?hours Result:Showed extensive vacuolation and formation of autophagosome like structures in the cytoplasm.Showed an increased expression of LC3, an autophagy marker.Western Blot Analysis Cell Line:SK-N-DZ and SK-N-BE neuroblastoma cells Concentration:0.1, 1 μM Incubation Time:48 hours Result:Inhibited GSK-3 leading to a decreased expression of the NF-κB target XIAP.
  • In Vivo
    Animal Model:NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) mice Dosage:40 mg/kg Administration:Every other day; for 17 days Result:Had single-agent antitumor activity in a mouse model of MCL.
  • Synonyms
    ——
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    GSK-3
  • Recptor
    GSK-3β
  • Research Area
    Others
  • Indication
    Myelofibrosis

Chemical Information

  • CAS Number
    1034895-42-5
  • Formula Weight
    404.35
  • Molecular Formula
    C22H13FN2O5
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:97 mg/mL (239.89mM; Need ultrasonic)
  • SMILES
    Cn1cc(C2=C(C(=O)NC2=O)c2coc3ccc(F)cc23)c2cc3OCOc3cc12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Ugolkov AV, et al. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs. 2018 Sep;29(8):717-724.
molnova catalog
related products
  • GS87

    GS87 is a highly specific inhibitor of GSK3 (glycogen synthase kinase 3) that induces extensive differentiation of AML cells.GS87 potently inhibits growth of AML cells in mice with little effect on normal bone marrow cells. GS87 causes terminal differentiation of AML cells.

  • GSK3a-IN-38

    GSK3a-IN-38 is a novel small molecule compound that has inhibitory effects on GSK-3a.

  • 1-Azakenpaullone

    1-Azakenpaullone is an analog of kenpaullone and is a potent, selective GSK3β inhibitor with IC50 of 18 nM.